(
|
|
|
- きみのしん たかぎ
- 5 years ago
- Views:
Transcription
1 (
2 2
3 3
4 4
5 Sx x C 2 C 2 5
6 6
7 Arnold Demain: TIBTEC JAUARY 2000) 7
8 8
9 2 2 Duocarmycin B2 Mitomicin C Br ES RES DC102 DC14E Kaprimycin A1 Staurosporine Manumycin A Clecarmycin wortmannin Saintopin DC92-B 2 Tetrocarcin A Sapurimycin 2 RES MS-681a 2 2 Fortimicin A K-252a GE3 - Secanacarcin A + 2 UC-01 UCE6 KS-501 UCA1064A Cl 2 Limphostin 2 Calphostin C AS-186a RP RES Trioxoacarcin 2 2 Belactosin A UCS Gilvocarcin V MS Sagamicin erboxidiene Pyrronamycin A Cl Cl Cl Cl Cl Cl KS-504a 2 Cl MY336 UC9 Leinamycin Q uinocarcin Destruxin EI β1 6 Glucose Glucose n-1 S S + 3 C - (Caproic acid) m S C C 3 S 9 PS-996 n=10-30 m=5-15
10 Penicillin Penicillin Amino Fradiomycin Kanamycin Gentamicin Micronomicin - glycoside Streptomycin Tobramycin Astromicin Tetracyclin Tetracyclin Erythromycin Josamycin Macrolide Spiramycin Kitasamycin Peptide Gramicidin Bacitracin Vancomycin Enramycin thers Cycloserine Fosfomycin Clavulanic acid Polyene ystatin Azalomycin F -macrolide Amphotericin B Pentamycin thers Griseofulvin Aureothricin Siccanin Actinomycin D Carzinophilin Doxorubicin Aclarubicin Chromomycin A3 Bleomycin Peplomycin eocarzinostatin *Mitomycin C 58, 17,
11 Mizoribine(Bredinin) Tacrolimus(FK-506) Ciclosporin(Cyclosporin A) Gusperimus(15-deoxyspergualin) Pravastatin (Mevalotin) Simvastatin Acarbose Voglibose 58, 17,
12 20g/L 70%) Mortierella alpina 12
13 & 13
14 L- L-
15 D-p- -carbamoyl D-p-hydroxy-PhenylGlycine D- D- Pseudomonas sp. D-p-hydroxy PhenylGlycine 15
16 8 2 Rhodococcus rhodochrous 16
17 C 2 - L-Proline trans-4-yp C 2 17
18 Glucose ATP ADP ATP ADP 2 C 2 Glucose Acids 2 C 2 Acids 18
19 19
20 E.coli sugartransferase sugarnucleotide biosynthesisgenes E.coli sugartransferase sugarnucleotide biosynthesisgenes E.coli sugar Transferase sugarnucleotide biosynthesisgenes β β α β β ABC GMP 1,4-Galactosyl Transferase 1,3-Galactosyl Transferase 1,4-Galactosyl Transferase 1,4-GalAc Transferase 1,3-GalAc Transferase C. ammoniagenes ABC α2,3-siaryl Transferase α2,6-siaryl Transferase α1,2-fucocyl Transferase α1,3-fucosyltransferase etc. ABC 2'-Fucosyl-lactose 3-Fucosyl-lactose 3'-Sialyl-3-fucosyllactose Lacto-di-fuco-tetraose Lacto--fuco-pentaose I Lacto--fuco-pentaose II Lacto--fuco-pentaose V LS-Tetra-saccharide a LS-Tetra-saccharide b 20 GM1 GD1 etc.
21 ED MGF MGF Minimum Genome Cell 21 ED)
22 22 ED)
23 TG Y Y Y Y 23
24 2004
25 / P 25
26 ( 26
27 ( IgE 20 27
28 ( (1) (2) B 28
29 ( 29
30 ( 2,000 1,500 1, ReoPro Synagis 668 1,607 Rituxan 1,261 Remicade 694 erceptin Zevalin Mylotarg Campath - 50 KT-3 70 Zenapax 50 Simulect umira 30 Xolair
31 31 Stage Phase III Phase II Phase I Total Chimera umanized uman Mouse thers PharmaProject ( (
32 32 (
33 ( 33
34 ( ADCC Asn
35 ADCC ( 35
36 ( 36
37 / ( vial MCB/WCB 37
38 ( 38
39 4 kl Pacific Biologics ( 39
40 ( 40
41 ( 8 kl CM 0.9 kl x kl x 2 10 kl x 8 Pacific Biologics CM 4 kl 41
42 42
43 43
1 911 9001030 9:00 A B C D E F G H I J K L M 1A0900 1B0900 1C0900 1D0900 1E0900 1F0900 1G0900 1H0900 1I0900 1J0900 1K0900 1L0900 1M0900 9:15 1A0915 1B0915 1C0915 1D0915 1E0915 1F0915 1G0915 1H0915 1I0915
Microsoft Word - antibiotics-052.doc
β β β 1 !"#$%&'()* >?#,-% @AB 2;/0%,#FG% /0%, "-%,.% :9% #.-% 12-%,9%!"#$% +"# +"#%
( ) ( ) 20 11 11-13 15 20 21 ( ) 114cm 100cm 85cm () () 11 18 19 19-25 26 ( 1 ) 1 2 10 ( ) () 11 16 19 21 24-13 20 3 20 ( ) ( ) 14 15 19 20 23 29 13 20 4/15 600 400 5 7 1 8 5 7 20 3 1999 1000 100 86
1 (1) (2)
1 2 (1) (2) (3) 3-78 - 1 (1) (2) - 79 - i) ii) iii) (3) (4) (5) (6) - 80 - (7) (8) (9) (10) 2 (1) (2) (3) (4) i) - 81 - ii) (a) (b) 3 (1) (2) - 82 - - 83 - - 84 - - 85 - - 86 - (1) (2) (3) (4) (5) (6)
- 2 -
- 2 - - 3 - (1) (2) (3) (1) - 4 - ~ - 5 - (2) - 6 - (1) (1) - 7 - - 8 - (i) (ii) (iii) (ii) (iii) (ii) 10 - 9 - (3) - 10 - (3) - 11 - - 12 - (1) - 13 - - 14 - (2) - 15 - - 16 - (3) - 17 - - 18 - (4) -
2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4 4 4 2 5 5 2 4 4 4 0 3 3 0 9 10 10 9 1 1
1 1979 6 24 3 4 4 4 4 3 4 4 2 3 4 4 6 0 0 6 2 4 4 4 3 0 0 3 3 3 4 3 2 4 3? 4 3 4 3 4 4 4 4 3 3 4 4 4 4 2 1 1 2 15 4 4 15 0 1 2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4
20 15 14.6 15.3 14.9 15.7 16.0 15.7 13.4 14.5 13.7 14.2 10 10 13 16 19 22 1 70,000 60,000 50,000 40,000 30,000 20,000 10,000 0 2,500 59,862 56,384 2,000 42,662 44,211 40,639 37,323 1,500 33,408 34,472
I? 3 1 3 1.1?................................. 3 1.2?............................... 3 1.3!................................... 3 2 4 2.1........................................ 4 2.2.......................................
研修コーナー
l l l l l l l l l l l α α β l µ l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
ウェブ23A rev2
23A 23A.1 23A.2 23A.3 23A.4 23A.5 23A.5.1 23A.5.2 23A.5.3 23A.5.4 23A.5.5 Fischer 23A.6 23A.6 23A.7 1 carbohydratehydrate of carbon n ( 2 ) m saccharide monosaccharide disaccharide oligosaccharide 4 10
cm H.11.3 P.13 2 3-106-
H11.3 H.11.3 P.4-105- cm H.11.3 P.13 2 3-106- 2 H.11.3 P.47 H.11.3 P.27 i vl1 vl2-107- 3 h vl l1 l2 1 2 0 ii H.11.3 P.49 2 iii i 2 vl1 vl2-108- H.11.3 P.50 ii 2 H.11.3 P.52 cm -109- H.11.3 P.44 S S H.11.3
_0212_68<5A66><4EBA><79D1>_<6821><4E86><FF08><30C8><30F3><30DC><306A><3057><FF09>.pdf
untitled
( ) 200133 3 3 3 3, 7 347 57 10 i ii iii -1- -2- -3- -4- 90011001700mm -5- 4.2 1991 73.5 44.4 7.4 10.5 10.5 7.4 W 3 H 2.25 H 2.25 7.4 51.8 140.6 88.8 268.8m 5,037.9m 2 2mm 16cm916cm 10.5 W 3 H 2.25 62.8
株式会社日清製粉グループ本社 第158期中間事業報告書
C O N T E N T S...1...3...5...7...9...11...12...13...14 1 2 3 4 3.7% 5.8% 8.5% 70,100kL 81.2% 0.8% 25 20 15 10 5 0 9.18 9.54 9.74 9.62 9.65 9.71 21.04 21.97 22.44 22.23 8.54 22.31 22.45 20.41 15 12 9 6
89 91 93 95 97 99 101 103 105 107 109 111 113 115 H 117 119 l l 121 l l 123 125 127 129 l l l l 131 kl kl kl kl 133 135 137 139 141 143 145 147 149 151 153 155 157 159
1,000 700-1 -
23 9 () - 0 - 1,000 700-1 - 2 3 ( 16:0017:00 ( 8:15 8:30 10:3010:50 8:00 8:10 8:10 9:30 11:0011:20 11:3015:30 16:0016:40 16:0016:10 16:50 21:00 4:00 4:006:00 6:00 6:1511:00 11:3012:00 12:3014:30 (1) ()
44 4 I (1) ( ) (10 15 ) ( 17 ) ( 3 1 ) (2)
(1) I 44 II 45 III 47 IV 52 44 4 I (1) ( ) 1945 8 9 (10 15 ) ( 17 ) ( 3 1 ) (2) 45 II 1 (3) 511 ( 451 1 ) ( ) 365 1 2 512 1 2 365 1 2 363 2 ( ) 3 ( ) ( 451 2 ( 314 1 ) ( 339 1 4 ) 337 2 3 ) 363 (4) 46
1. (1) 1/
2005 11 30 2006 03 31 1-1-2 [ ] 7-12 SMBC 4 1 27 1 18 1. (1) 1/5 1 2 32 1/5 1 2006 3 11 200 2006 1 1/5 20 20 30 CM 10 TVCM15 BB 2006 3 31 26 3 5 2 1 4 3 2 3 (2) (1) 2. (1) 1 2006/03/31 1,680,877,606 1
i ii i iii iv 1 3 3 10 14 17 17 18 22 23 28 29 31 36 37 39 40 43 48 59 70 75 75 77 90 95 102 107 109 110 118 125 128 130 132 134 48 43 43 51 52 61 61 64 62 124 70 58 3 10 17 29 78 82 85 102 95 109 iii
01_教職員.indd
T. A. H. A. K. A. R. I. K. O. S. O. Y. O. M. K. Y. K. G. K. R. S. A. S. M. S. R. S. M. S. I. S. T. S. K.T. R. T. R. T. S. T. S. T. A. T. A. D. T. N. N. N. Y. N. S. N. S. H. R. H. W. H. T. H. K. M. K. M.
1 2 3 4 5 6 X Y ABC A ABC B 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 13 18 30 P331 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 ( ) 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59
26 2 3 4 5 8 9 6 7 2 3 4 5 2 6 7 3 8 9 3 0 4 2 4 3 4 4 5 6 5 7 6 2 2 A B C ABC 8 9 6 3 3 4 4 20 2 6 2 2 3 3 4 4 5 5 22 6 6 7 7 23 6 2 2 3 3 4 4 24 2 2 3 3 4 4 25 6 2 2 3 3 4 4 26 2 2 3 3 27 6 4 4 5 5
mogiJugyo_slide_full.dvi
a 2 + b 2 = c 2 (a, b, c) a 2 a 2 = a a a 1/ 78 2/ 78 3/ 78 4/ 78 180 5/ 78 http://www.kaijo.ed.jp/ 6/ 78 a, b, c ABC C a b B c A C 90 a 2 + b 2 = c 2 7/ 78 C a b a 2 +b 2 = c 2 B c A a 2 a a 2 = a a 8/
A B A E
10533-68-3955 10533-68-3955 10533-68-3804 RP A-6 10533-68-3804 10533-69-9615 10533-57-2161 B-2 10533-68-2274 10533-68-2221 10533-67-6282 A-6 10533-57-2161 E-3 10533-68-5161 10533-68-3553 D-2 D-2 10533-69-5258
Microsoft Word - 化学構造式集 doc
抗生物質 (Antibiotics.) (1) 複素環式のもの (eterocyclic) - ノボビオシン (ovobiocin) - セファロスポリン類 (ephalosporins) セファロスポリン核を有するもの :R1 R2 が変わる (Those which have cephalosporin nucleus: R1 and R2 to change.) R 1 R 2 -- セファロスポリン
平成20年5月 協会創立50年の歩み 海の安全と環境保全を目指して 友國八郎 海上保安庁 長官 岩崎貞二 日本船主協会 会長 前川弘幸 JF全国漁業協同組合連合会 代表理事会長 服部郁弘 日本船長協会 会長 森本靖之 日本船舶機関士協会 会長 大内博文 航海訓練所 練習船船長 竹本孝弘 第二管区海上保安本部長 梅田宜弘
![Œ{Ł¶/1ŒÊ −ªfiª„¾ [ 1…y†[…W ]](/thumbs/50/26134150.jpg "Œ{Ł¶/1ŒÊ −ªfiª„¾ [ 1…y†[…W ]")
物理化学I-第12回(13).ppt
I- 12-1 11 11.1 2Mg(s) + O 2 (g) 2MgO(s) [Mg 2+ O 2 ] Zn(s) + Cu 2+ (aq) Zn 2+ (aq) + Cu(s) - 2Mg(s) 2Mg 2+ (s) + 4e +) O 2 (g) + 4e 2O 2 (s) 2Mg(s) + O 2 (g) 2MgO(s) Zn(s) Zn 2+ (aq) + 2e +) Cu 2+ (aq)
取扱説明書
ED-601 ED-501 ED-401 2 3 4 23 14 5 6 18 10 7 1 2 6 3 4 8 9 16 16 16 12 1 2 18 10 2 1 5 12 11 1 2 1 2 12 1 2 13 16 14 3 2 4 1 1 2 16 3 4 18 15 1 2 16 2 3 1 1 2 3 18 17 18 22 19 D A C 20 A B 22 B C D 22
2 ID POS 1... 1 2... 2 2.1 ID POS... 2 2.2... 3 3... 5 3.1... 5 3.2... 6 3.2.1... 6 3.2.2... 7 3.3... 7 3.3.1... 7 3.3.2... 8 3.3.3... 8 3.4... 9 4... 11 4.1... 11 4.2... 15 4.3... 27 5... 35... 36...
CRA3689A
AVIC-DRZ90 AVIC-DRZ80 2 3 4 5 66 7 88 9 10 10 10 11 12 13 14 15 1 1 0 OPEN ANGLE REMOTE WIDE SET UP AVIC-DRZ90 SOURCE OFF AV CONTROL MIC 2 16 17 1 2 0 0 1 AVIC-DRZ90 2 3 4 OPEN ANGLE REMOTE SOURCE OFF
１
10 1113 14 1516 1719 20 21 22 2324 25 2627 i 2829 30 31 32 33 3437 38 3941 42 4344 4547 48 4950 5152 53 5455 ii 56 5758 59 6061 iii 1 2 3 4 5 6 7 8 9 10 PFI 30 20 10 PFI 11 12 13 14 15 10 11 16 (1) 17
人芯経営論 ･･･リーダーシップ考②
2009/12/15 2009/11/17 2009/11/16 2009/10/19 2009/10/15 2009/10/1 2009/9/17 2009/9/1 2009/8/17 2009/8/17 2009/8/14 2009/8/12 2009/7/28 2009/7/17 2009/7/15 2009/6/24 2009/6/18 2009/6/15 2009/5/20 2009/5/15
1. 2001 10 2 480 2003 8 1.6 5 2. 90 3. 4. 5. 5 60 6. 1 2 2 2 4 5 5 6 6 6 7 10 10 10 12 12 12 14 14 15 15 60 15 17 17 18 2001 10 2 480 2003 8 1.6 5 1 1.8 3.6 1 6.8 1.5 3 3 5 6065 70 5 1.22004 1 1 2002 4
31, 21% 24, 17% 8, 5% 23, 16% 24, 16% 91, 62% 19, 13% 39, 27% 33, 23% 73 48 57 51 31 1 9 13.0% 7.4% 5.3% 12.5% 17.1% 13.2% 17.9% 4.5% 36.4% 56.5% 40.7% 36.8% 50.0% 67.1% 56.3% 65.8% 75.0% 26.0% 37.0%
37 27.0% 26 19.0% 74 54.0% 9 6.4% 13 9.2% 28 19.9% 26 18.4% 37 26.2%. 24 17.0% 99 69 75 59 39 1 6 4.5% 1.4% 7.7% 2.9% 25.0% 17.9% 20.8% 50.0% 41.7% 47.0% 51.4% 54.3% 61.5% 57.1% 55.6% 42.4% 50.0% 58.3%
% 32.3 DI DI
2011 7 9 28.1 41.4 30.5 35.8 31.9% 32.3 DI 18.2 2.4 8.1 3.5 DI 9.4 32.2 0.0 25.9 2008 1 3 2 3 34.8 65.2 46.753.8 1 2 8.82.9 43.1 10 3 DI 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
2 DI 28 7 1 37 28 4 18 27 11 21 5 2 26 4 5 1 15 2 25 3 35 4 17 7 5 48 76 31 47 17 2 92 12 2 2 4 6 8 1 12 1 2 4 1 12 13 18 19 3 42 57 57 1 2 3 4 5 6 1 1 1 3 4 4 5 5 5.5 1 1.5 2 2.5 3 3.5 4 4.5 5
3 DI 29 7 1 5 6 575 11 751, 13 1,1,25 6 1,251,5 2 1,51,75 1,752, 1 2,2,25 2,252,5 2,53, 3,3,5 3,5 5 1 15 2 25 3 5 6 575 12 751, 21 1,1,25 27 1,251,5 9 1,51,75 1,752, 1 2,2,25 2 2,252,5 2,53, 2 3,3,5
(1) PQ (2) () 2 PR = PR P : P = R : R (2) () = P = P R M = XM : = M : M (1) (2) = N = N X M 161 (1) (2) F F = F F F EF = F E
5 1 1 1.1 2 159 O O PQ RS OR P = PQ P O M MQ O (1) M P (2) P : P R : R () PR P 160 > M : = M : M X (1) N = N M // N X M (2) M 161 (1) E = 8 = 4 = = E = (2) : = 2 : = E = E F 5 F EF F E 5 1 159 (1) PQ (2)
Microsoft Word - ランチョンプレゼンテーション詳細.doc
PS1-1-1 PS1-1-2 PS1-1-3 PS1-1-4 PS1-1-5 PS1-1-6 PS1-1-7 PS1-1-8 PS1-1-9 1 25 12:4514:18 25 12:4513:15 B PS1-1-10 PS1-2-1 PS1-2-2 PS1-2-3 PS1-2-4 PS1-2-5 PS1-2-6 25 13:1513:36 B PS1-2-7 PS1-3-1 PS1-3-2
O1-1 O1-2 O1-3 O1-4 O3-1 O3-2 O3-3 O3-4 ES1-1 ES1-2 ES1-3 ES2-1 ES2-2 ES2-3 ES2-4 O2-1 O2-2 O2-3 O2-4 O2-5 O4-1 O4-2 O4-3 O4-4 O5-1 O5-2 O5-3 O5-4 O7-1 O7-2 O7-3 O7-4 O9-1 O9-2 O9-3 O9-4 O12-1 O12-2
59 1 2 3 6 7 8 10 12 13 14 15 16 17 18 19 20 21 23 24 25 26 46 49 30 33 36 38 39 40 42 44 41 45 56 43 52 2 3 4 5 6 7 8 9 q w e r t y u i o!0!1!2!3!4!5!6!7!8!9 @0 @1 @2 @3 @4 10 @5 J @6 @7 @8 @9 #0 #1 #2
> > <., vs. > x 2 x y = ax 2 + bx + c y = 0 2 ax 2 + bx + c = 0 y = 0 x ( x ) y = ax 2 + bx + c D = b 2 4ac (1) D > 0 x (2) D = 0 x (3
13 2 13.0 2 ( ) ( ) 2 13.1 ( ) ax 2 + bx + c > 0 ( a, b, c ) ( ) 275 > > 2 2 13.3 x 2 x y = ax 2 + bx + c y = 0 2 ax 2 + bx + c = 0 y = 0 x ( x ) y = ax 2 + bx + c D = b 2 4ac (1) D >
(1) θ a = 5(cm) θ c = 4(cm) b = 3(cm) (2) ABC A A BC AD 10cm BC B D C 99 (1) A B 10m O AOB 37 sin 37 = cos 37 = tan 37
4. 98 () θ a = 5(cm) θ c = 4(cm) b = (cm) () D 0cm 0 60 D 99 () 0m O O 7 sin 7 = 0.60 cos 7 = 0.799 tan 7 = 0.754 () xkm km R km 00 () θ cos θ = sin θ = () θ sin θ = 4 tan θ = () 0 < x < 90 tan x = 4 sin
EV200R I II III 1 2 3 4 5 6 7 8 9 10 1 2 3 11 4 5 12 6 13 1 2 14 3 4 15 5 16 1 2 17 3 18 4 5 19 6 20 21 22 123 456 123 456 23 1 2 24 3 4 25 5 3 26 4 5 6 27 7 8 9 28 29 30 31 32 1 2 33 3 4 34 1 35 2 1
訪問看護ステーションにおける安全性及び安定的なサービス提供の確保に関する調査研究事業報告書
1... 1 2... 3 I... 3 II... 3 1.... 3 2....15 3....17 4....19 5....25 6....34 7....38 8....48 9....58 III...70 3...73 I...73 1....73 2....82 II...98 4...99 1....99 2....104 3....106 4....108 5.... 110 6....
koji07-01.dvi
2007 I II III 1, 2, 3, 4, 5, 6, 7 5 10 19 (!) 1938 70 21? 1 1 2 1 2 2 1! 4, 5 1? 50 1 2 1 1 2 2 1?? 2 1 1, 2 1, 2 1, 2, 3,... 3 1, 2 1, 3? 2 1 3 1 2 1 1, 2 2, 3? 2 1 3 2 3 2 k,l m, n k,l m, n kn > ml...?
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 ( ) 24 25 26 27 28 29 30 ( ) ( ) ( ) 31 32 ( ) ( ) 33 34 35 36 37 38 39 40 41 42 43 44 ) i ii i ii 45 46 47 2 48 49 50 51 52 53 54 55 56 57 58
untitled
i ii (1) (1) (2) (1) (3) (1) (1) (2) (1) (3) (1) (1) (2) (1) (3) (2) (3) (1) (2) (3) (1) (1) (1) (1) (2) (1) (3) (1) (2) (1) (3) (1) (1) (1) (2) (1) (3) (1) (1) (2) (1) (3)
